Please login to the form below

Not currently logged in

Approvals of generic Eloxatin suspended

A US appeals court has temporarily suspended approvals of generic versions of sanofi-aventis' Eloxatin, delaying competition to its fifth-biggest medicine

A US appeals court has temporarily suspended approvals of generic versions of sanofi-aventis' Eloxatin (oxaliplatin), delaying competition to its fifth-biggest medicine.

France's largest drugmaker has contested the US Food and Drug Administration's (FDA) decision to approve copies of the treatment. The ruling forces rivals, including Hospira and Teva who recently obtained FDA approval, to halt shipments of the drug.

Teva spokesperson Denise Bradley confirmed that the company is "not shipping further product until the legal issue is resolved… We are hopeful to have a decision in the near future."

Hospira stated in a US Securities and Exchange Commission filing that the suspension remains in effect "until such time as the court has an opportunity to consider arguments on this matter."

Eloxatin generated €1.35bn ($1.9bn) in sales for sanofi-aventis last year. The company is under pressure as several of its best-selling drugs, including the blood-thinner Plavix, face generic competition.

18th August 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...